Oncimmune (ONC) Competitors

Oncimmune (LON:ONC) and SkinBioTherapeutics (LON:SBTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation.

Does the MarketBeat Community believe in ONC or SBTX?

Oncimmune received 21 more outperform votes than SkinBioTherapeutics when rated by MarketBeat users. However, 60.26% of users gave SkinBioTherapeutics an outperform vote while only 59.13% of users gave Oncimmune an outperform vote.

Company	Underperform	Outperform
Oncimmune	Outperform Votes 68 59.13%	Underperform Votes 47 40.87%
SkinBioTherapeutics	Outperform Votes 47 60.26%	Underperform Votes 31 39.74%

Do analysts recommend ONC or SBTX?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncimmune	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
SkinBioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Do insiders and institutionals hold more shares of ONC or SBTX?

25.0% of Oncimmune shares are owned by institutional investors. Comparatively, 16.6% of SkinBioTherapeutics shares are owned by institutional investors. 31.0% of Oncimmune shares are owned by insiders. Comparatively, 20.4% of SkinBioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Which has more volatility and risk, ONC or SBTX?

Oncimmune has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, SkinBioTherapeutics has a beta of 2.01, suggesting that its stock price is 101% more volatile than the S&P 500.

Does the media refer more to ONC or SBTX?

In the previous week, Oncimmune had 1 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 1 mentions for Oncimmune and 0 mentions for SkinBioTherapeutics. Oncimmune's average media sentiment score of 0.59 beat SkinBioTherapeutics' score of 0.00 indicating that Oncimmune is being referred to more favorably in the media.

Company	Overall Sentiment
Oncimmune	Positive
SkinBioTherapeutics	Neutral

Which has stronger earnings & valuation, ONC or SBTX?

SkinBioTherapeutics has lower revenue, but higher earnings than Oncimmune. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Oncimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncimmune	£1.21M	9.68	-£3.14M	-£0.03	-526.50
SkinBioTherapeutics	£21.95K	1,712.49	-£2.88M	-£0.02	-831.25

Is ONC or SBTX more profitable?

Oncimmune has a net margin of 586.08% compared to SkinBioTherapeutics' net margin of 0.00%. SkinBioTherapeutics' return on equity of -118.63% beat Oncimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncimmune	586.08%	-760.96%	-26.38%
SkinBioTherapeutics	N/A	-118.63%	-61.18%

Summary

Oncimmune beats SkinBioTherapeutics on 9 of the 15 factors compared between the two stocks.